0.00Open0.15Pre Close0 Volume23 Open Interest7.50Strike Price0.00Turnover276.09%IV60.10%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.0301Delta0.0066Gamma122.80Leverage Ratio-0.0226Theta-0.0003Rho-3.70Eff Leverage0.0026Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet